Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Genes, p53"" wg kryterium: Temat


Tytuł :
Upregulation of mir-132 induces dopaminergic neuronal death via activating SIRT1/P53 pathway.
Autorzy :
Qazi TJ; Key Laboratory of Molecular Medicine and Biotherapy, Department of Biology, School of Life Science, Beijing Institute of Technology, Beijing, 100081, China.
Lu J; Key Laboratory of Molecular Medicine and Biotherapy, Department of Biology, School of Life Science, Beijing Institute of Technology, Beijing, 100081, China.
Duru L; Key Laboratory of Molecular Medicine and Biotherapy, Department of Biology, School of Life Science, Beijing Institute of Technology, Beijing, 100081, China.
Zhao J; School of Material Science and Engineering, Department of Materials Processing Engineering, Beijing Institute of Technology, Beijing, 100081, China. Electronic address: .
Qing H; Key Laboratory of Molecular Medicine and Biotherapy, Department of Biology, School of Life Science, Beijing Institute of Technology, Beijing, 100081, China. Electronic address: .
Pokaż więcej
Źródło :
Neuroscience letters [Neurosci Lett] 2021 Jan 01; Vol. 740, pp. 135465. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Death/*physiology
Dopaminergic Neurons/*physiology
Genes, p53/*physiology
MicroRNAs/*biosynthesis
Signal Transduction/*physiology
Sirtuin 1/*physiology
Animals ; Apoptosis Regulatory Proteins/biosynthesis ; Apoptosis Regulatory Proteins/genetics ; Cell Line ; Cell Survival/genetics ; Genes, p53/genetics ; Humans ; Mice ; Mice, Transgenic ; MicroRNAs/genetics ; Parkinson Disease, Secondary/chemically induced ; Parkinson Disease, Secondary/genetics ; Signal Transduction/genetics ; Sirtuin 1/genetics
Czasopismo naukowe
Tytuł :
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.
Autorzy :
Monti P; Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Lionetti M; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.
De Luca G; Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Menichini P; Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Recchia AG; Biotechnology Research Unit, Aprigliano, A.O./ASP of Cosenza, 87100, Cosenza, Italy.
Matis S; Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Colombo M; Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Fabris S; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Speciale A; Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Barbieri M; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Gentile M; Hematology Unit, Department of Onco-Hematology, A.O. of Cosenza, 87100, Cosenza, Italy.
Zupo S; Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Dono M; Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Ibatici A; Hematology Unit and Bone Marrow Transplantation, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Neri A; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Ferrarini M; Department of Experimental Medicine, University of Genoa, 16132, Genoa, Italy.
Fais F; Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Department of Experimental Medicine, University of Genoa, 16132, Genoa, Italy.
Fronza G; Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
Cutrona G; Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Morabito F; Biotechnology Research Unit, Aprigliano, A.O./ASP of Cosenza, 87100, Cosenza, Italy. .; Department of Hematology and Bone Marrow Transplant Unit, Augusta Victoria Hospital, Jerusalem, Israel. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 28; Vol. 10 (1), pp. 18427. Date of Electronic Publication: 2020 Oct 28.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, p53*
Time-to-Treatment*
Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Male ; Middle Aged ; Mutation ; Prospective Studies
Czasopismo naukowe
Tytuł :
Functional interplay among thiol-based redox signaling, metabolism, and ferroptosis unveiled by a genetic variant of TP53 .
Autorzy :
Leu JI; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Murphy ME; Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA 19104 .
George DL; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Oct 27; Vol. 117 (43), pp. 26804-26811. Date of Electronic Publication: 2020 Oct 14.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Ferroptosis*
Genes, p53*
Oxidation-Reduction*
Activating Transcription Factor 4/*metabolism
Sulfhydryl Compounds/*metabolism
Animals ; Cell Line ; Coenzyme A/metabolism ; Glutathione/metabolism ; Glycolysis ; Homeostasis ; Humans ; Male ; Mice ; Protein Processing, Post-Translational
Czasopismo naukowe
Tytuł :
Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models.
Autorzy :
Kunimura N; Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Kitagawa K; Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Sako R; Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Narikiyo K; Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Tominaga S; Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Bautista DS; Sibiono GeneTech Co. Ltd, Shenzhen, China.
Xu W; Sibiono GeneTech Co. Ltd, Shenzhen, China.
Fujisawa M; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Shirakawa T; Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. .; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 15; Vol. 10 (1), pp. 17464. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, p53*
Antineoplastic Agents/*therapeutic use
Genetic Therapy/*methods
Immune Checkpoint Inhibitors/*therapeutic use
Immunotherapy/*methods
Urogenital Neoplasms/*genetics
Urogenital Neoplasms/*therapy
Adenoviridae ; Animals ; Cell Line, Tumor ; Isografts ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C3H ; Mice, Inbred C57BL ; Programmed Cell Death 1 Receptor/immunology ; RNA, Messenger/metabolism
Czasopismo naukowe
Tytuł :
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Autorzy :
Bories P; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.; Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.; Réseau Onco-occitanie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Prade N; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Lagarde S; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Cabarrou B; Unité de biostatistique, Institut Claudius Régaud, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Largeaud L; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Plenecassagnes J; Unité de bioinformatique, Institut Claudius Régaud, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Luquet I; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
De Mas V; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Filleron T; Unité de biostatistique, Institut Claudius Régaud, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Cassou M; Unité de bioinformatique, Institut Claudius Régaud, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Sarry A; Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Fornecker LM; Service d'Onco-Hématologie, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.
Simand C; Service d'Onco-Hématologie, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.
Bertoli S; Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Recher C; Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Delabesse E; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Oct 01; Vol. 15 (10), pp. e0238795. Date of Electronic Publication: 2020 Oct 01 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, p53*
Mutation*
Antimetabolites, Antineoplastic/*therapeutic use
Azacitidine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Tumor Suppressor Protein p53/*genetics
Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Female ; France/epidemiology ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Registries
Czasopismo naukowe
Tytuł :
Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Autorzy :
Midorikawa Y; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan. .; Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
Yamamoto S; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Tatsuno K; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Renard-Guillet C; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Tsuji S; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Hayashi A; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Ueda H; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Fukuda S; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Fujita T; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Katoh H; Department of Preventive Medicine, University of Tokyo, Tokyo, Japan.
Ishikawa S; Department of Preventive Medicine, University of Tokyo, Tokyo, Japan.
Covington KR; Baylor College of Medicine's Human Genome Sequencing Center, Houston, Texas.
Creighton CJ; Baylor College of Medicine's Human Genome Sequencing Center, Houston, Texas.
Sugitani M; Department of Pathology, Nihon University School of Medicine, Tokyo, Japan.
Wheeler DA; Baylor College of Medicine's Human Genome Sequencing Center, Houston, Texas.
Shibata T; Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Nagae G; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.
Takayama T; Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
Aburatani H; Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2020 Sep 15; Vol. 80 (18), pp. 3810-3819. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, p53*
Carcinoma, Hepatocellular/*genetics
Liver Neoplasms/*genetics
Wnt Proteins/*genetics
Carcinoma, Hepatocellular/pathology ; DNA Methylation ; DNA, Neoplasm/isolation & purification ; Disease Progression ; Epigenesis, Genetic ; Gene Dosage ; Gene Drive Technology ; Gene Expression ; Genes, cdc ; Histone-Lysine N-Methyltransferase/genetics ; Humans ; Liver Neoplasms/pathology ; Mutation ; Myeloid-Lymphoid Leukemia Protein/genetics ; Oncogene Protein v-akt/genetics ; Phosphatidylinositol 3-Kinases/genetics ; Probability ; RNA, Neoplasm/isolation & purification ; Reverse Transcriptase Polymerase Chain Reaction ; Sequence Analysis, DNA ; Telomerase/genetics ; Transcriptional Activation ; Up-Regulation ; beta Catenin/genetics
Czasopismo naukowe
Tytuł :
Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15 Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma.
Autorzy :
Chen SMY; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Li B; Department of Pathology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Nicklawsky AG; Department of Pediatrics, Department of Biostatistics and Informatics, Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Krinsky AL; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Brunetti T; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Woolaver RA; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Wang X; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Chen Z; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Young CD; Department of Pathology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Gao D; Department of Pediatrics, Department of Biostatistics and Informatics, Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Wang XJ; Department of Pathology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.; Veterans Affairs Medical Center, VA Eastern Colorado Health Care System, Aurora, CO 80045, USA.
Wang JH; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Sep 09; Vol. 21 (18). Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article
MeSH Terms :
Genes, p53*
Carcinoma, Squamous Cell/*etiology
Class I Phosphatidylinositol 3-Kinases/*metabolism
Head and Neck Neoplasms/*etiology
Keratin-15/*metabolism
Animals ; Carcinoma, Squamous Cell/mortality ; Class I Phosphatidylinositol 3-Kinases/genetics ; Head and Neck Neoplasms/mortality ; Humans ; Lymphocytes, Tumor-Infiltrating ; Mice, Transgenic ; Neoplasms, Experimental ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Three-Dimensional DNA Nanomachine Biosensor by Integrating DNA Walker and Rolling Machine Cascade Amplification for Ultrasensitive Detection of Cancer-Related Gene.
Autorzy :
Wu N; Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Box 332, Shenyang 110819, China.
Wang K; Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Box 332, Shenyang 110819, China.
Wang YT; Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Box 332, Shenyang 110819, China.
Chen ML; Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Box 332, Shenyang 110819, China.
Chen XW; Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Box 332, Shenyang 110819, China.
Yang T; Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Box 332, Shenyang 110819, China.
Wang JH; Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Box 332, Shenyang 110819, China.
Pokaż więcej
Źródło :
Analytical chemistry [Anal Chem] 2020 Aug 18; Vol. 92 (16), pp. 11111-11118. Date of Electronic Publication: 2020 Jul 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, p53*
Biosensing Techniques/*methods
DNA/*blood
Tumor Suppressor Protein p53/*genetics
DNA/chemistry ; DNA/genetics ; Gold/chemistry ; Humans ; Inverted Repeat Sequences ; Limit of Detection ; Magnetic Phenomena ; Metal Nanoparticles/chemistry ; Nucleic Acid Amplification Techniques/methods ; Nucleic Acid Hybridization ; Silver/chemistry
Czasopismo naukowe
Tytuł :
The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
Autorzy :
Ramelow J; Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, Florida, 33199, USA.; Biomolecular Sciences Institute, The Florida International University, Miami, Florida, 33199, USA.; Biological Sciences, College of Arts, Science and Education, The Florida International University, Miami, Florida, 33199, USA.
Brooks CD; Comprehensive Cancer Center at the Ohio State University College of Medicine, Columbus, OH, 43210, USA.
Gao L; Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, Florida, 33199, USA.
Almiman AA; Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, Florida, 33199, USA.
Williams TM; Comprehensive Cancer Center at the Ohio State University College of Medicine, Columbus, OH, 43210, USA.
Villalona-Calero MA; Biomolecular Sciences Institute, The Florida International University, Miami, Florida, 33199, USA. .
Duan W; Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, Florida, 33199, USA. .; Biomolecular Sciences Institute, The Florida International University, Miami, Florida, 33199, USA. .; Comprehensive Cancer Center at the Ohio State University College of Medicine, Columbus, OH, 43210, USA. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2020 Aug 08; Vol. 20 (1), pp. 738. Date of Electronic Publication: 2020 Aug 08.
Typ publikacji :
Journal Article
MeSH Terms :
Disease Models, Animal*
Genes, p53*
Mice, Transgenic*
Mutation*
Lung Neoplasms/*genetics
Age Factors ; Animals ; Crosses, Genetic ; Lung Neoplasms/pathology ; Mice ; Mice, Inbred A ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
p53: 800 million years of evolution and 40 years of discovery.
Autorzy :
Levine AJ; Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA. .
Pokaż więcej
Źródło :
Nature reviews. Cancer [Nat Rev Cancer] 2020 Aug; Vol. 20 (8), pp. 471-480. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms :
Evolution, Molecular*
Genes, p53/*genetics
Mutation/*genetics
Proto-Oncogene Proteins c-mdm2/*genetics
Signal Transduction/*genetics
Tumor Suppressor Protein p53/*genetics
Animals ; Biological Evolution ; Genes, BRCA1/physiology ; Genes, p53/physiology ; Genes, ras/genetics ; Humans ; Li-Fraumeni Syndrome/genetics ; Mutation/physiology ; Proto-Oncogene Proteins c-mdm2/metabolism ; Signal Transduction/physiology ; Stem Cells/metabolism ; Stress, Physiological/genetics ; Stress, Physiological/physiology ; Tumor Suppressor Protein p53/antagonists & inhibitors ; Tumor Suppressor Protein p53/metabolism ; Vertebrates/genetics ; Vertebrates/metabolism ; Vertebrates/physiology
Czasopismo naukowe
Tytuł :
Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
Autorzy :
Shen CC; Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan. .; Department of Physical Therapy, Hung Kuang University, No. 1650, Taiwan Boulevard Sec. 4 Taichung 407, Taichung, 43302, Taiwan. .; Department of Medicine, National Defense Medical Center, Taipei, Taiwan. .; Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. .; Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan. .; Basic Medical Education, Central Taiwan University of Science and Technology, Taichung, Taiwan. .
Cheng WY; Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Physical Therapy, Hung Kuang University, No. 1650, Taiwan Boulevard Sec. 4 Taichung 407, Taichung, 43302, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.
Lee CH; Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Neurosurgery, Neurological Institute, Taichung Tzu Chi Hospital, Taichung city, Taiwan.
Dai XJ; Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou city, China.
Chiao MT; Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan.
Liang YJ; Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan.
Hsieh WY; Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan.
Mao TF; Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan.
Lin GS; Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou city, China.
Chen SR; Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou city, China.
Liu BS; Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan.
Chen JP; Biostatistics Task Force, Taichung Veterans General Hospital, Taichung, Taiwan.
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2020 Jul 29; Vol. 20 (1), pp. 709. Date of Electronic Publication: 2020 Jul 29.
Typ publikacji :
Journal Article
MeSH Terms :
Codon*
Genes, p53*
Polymorphism, Genetic*
Arginine/*genetics
Brain Neoplasms/*genetics
Glioblastoma/*genetics
Proline/*genetics
Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Bevacizumab/therapeutic use ; Brain Neoplasms/drug therapy ; Female ; Gene Amplification ; Genotype ; Glioblastoma/drug therapy ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Pilot Projects ; Prognosis ; Retrospective Studies ; Sequence Analysis, DNA ; Taiwan ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Characterization of porcine p53 and its regulation by porcine Mdm2.
Autorzy :
Lang Y; College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
Yu C; College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
Tang J; College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
Li G; College of Veterinary Medicine, China Agricultural University, Beijing 100193, China. Electronic address: .
Bai R; College of Veterinary Medicine, China Agricultural University, Beijing 100193, China. Electronic address: .
Pokaż więcej
Źródło :
Gene [Gene] 2020 Jul 20; Vol. 748, pp. 144699. Date of Electronic Publication: 2020 Apr 22.
Typ publikacji :
Journal Article
MeSH Terms :
Genes, p53*
Gene Expression Regulation/*physiology
Proto-Oncogene Proteins c-mdm2/*physiology
Animals ; Cell Line ; Humans ; Mice ; Swine
Czasopismo naukowe
Tytuł :
Genetic Variation in the TP53 Gene and Patient Outcomes Following Severe Traumatic Brain Injury.
Autorzy :
Mellett K; School of Nursing, University of Pittsburgh, PA, USA.
Ren D; School of Nursing, University of Pittsburgh, PA, USA.
Alexander S; School of Nursing, University of Pittsburgh, PA, USA.
Osier N; School of Nursing, University of Texas at Austin, TX, USA.; Department of Neurology, Dell Medical School, University of Texas at Austin, TX, USA.
Beers SR; Department of Psychiatry, University of Pittsburgh, PA, USA.
Okonkwo DO; Department of Neurological Surgery, University of Pittsburgh, PA, USA.
Puccio AM; Department of Neurological Surgery, University of Pittsburgh, PA, USA.
Conley YP; Department of Human Genetics, School of Nursing, University of Pittsburgh, PA, USA.
Pokaż więcej
Źródło :
Biological research for nursing [Biol Res Nurs] 2020 Jul; Vol. 22 (3), pp. 334-340. Date of Electronic Publication: 2020 Mar 24.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Genes, p53*
Genotype*
Severity of Illness Index*
Brain Injuries, Traumatic/*genetics
Brain Injuries, Traumatic/*physiopathology
Tumor Suppressor Protein p53/*genetics
Adolescent ; Adult ; Aged ; Female ; Glasgow Coma Scale ; Glasgow Outcome Scale ; Humans ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; Prospective Studies ; Treatment Outcome ; United States ; Young Adult
Czasopismo naukowe
Tytuł :
Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines.
Autorzy :
Ödborn Jönsson L; Department of Women's and Children's Health, Karolinska Institutet, 171 64 Stockholm, Sweden.
Sahi M; Department of Women's and Children's Health, Karolinska Institutet, 171 64 Stockholm, Sweden.
Lopez-Lorenzo X; Department of Women's and Children's Health, Karolinska Institutet, 171 64 Stockholm, Sweden.
Keller FL; Department of Women's and Children's Health, Karolinska Institutet, 171 64 Stockholm, Sweden.
Kostopoulou ON; Department of Oncology-Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden.
Herold N; Department of Women's and Children's Health, Karolinska Institutet, 171 64 Stockholm, Sweden.; Pediatric Oncology, Astrid Lindgren Children's Hospital, Karolinska University Hospital Solna, 171 64 Stockholm, Sweden.
Ährlund-Richter L; Department of Women's and Children's Health, Karolinska Institutet, 171 64 Stockholm, Sweden.
Shirazi Fard S; Department of Women's and Children's Health, Karolinska Institutet, 171 64 Stockholm, Sweden.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Apr 01; Vol. 22 (7). Date of Electronic Publication: 2021 Apr 01.
Typ publikacji :
Journal Article
MeSH Terms :
Antibiotics, Antineoplastic/*therapeutic use
Cell Cycle Checkpoints/*drug effects
Doxorubicin/*therapeutic use
Neuroblastoma/*drug therapy
Antibiotics, Antineoplastic/pharmacology ; Cell Line, Tumor ; Doxorubicin/pharmacology ; Genes, p53 ; Humans ; Molecular Targeted Therapy ; Neuroblastoma/genetics
Czasopismo naukowe
Tytuł :
A surveillance clinic for children and adolescents with, or at risk of, hereditary cancer predisposition syndromes.
Autorzy :
Leedman N; University of Western Australia, Perth, WA, Australia.
Princehorn M; Perth Children's Hospital, Perth, WA, Australia.
Gottardo N; University of Western Australia, Perth, WA, Australia.; Telethon Kids Cancer Centre, Brain tumour Research Program, Telethon Kids Institute, Perth, WA, Australia.
Franklin C; Perth Children's Hospital, Perth, WA, Australia.
D'Souza R; Genetic Services of Western Australia, Perth, WA, Australia.
Kiraly-Borri CE; Genetic Services of Western Australia, Perth, WA, Australia.
Pokaż więcej
Źródło :
The Medical journal of Australia [Med J Aust] 2021 Apr; Vol. 214 (7), pp. 335-335.e1. Date of Electronic Publication: 2021 Mar 26.
Typ publikacji :
Letter
MeSH Terms :
Genetic Predisposition to Disease/*genetics
Neoplastic Syndromes, Hereditary/*genetics
Population Surveillance/*methods
Adolescent ; Australia/epidemiology ; Child ; Child, Preschool ; Early Detection of Cancer/methods ; Genes, p53/genetics ; Genetic Testing/methods ; Humans ; Infant ; Mutation ; Neoplastic Syndromes, Hereditary/diagnosis ; Neoplastic Syndromes, Hereditary/epidemiology ; Risk Assessment
Opinia redakcyjna
Tytuł :
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Autorzy :
Bouclet F; Service d'Hématologie clinique adultes et thérapie cellulaire, Hôpital Estaing, CHU Clermont-Ferrand, 1 place Lucie Aubrac, 63000, Clermont-Ferrand, France.
Calleja A; Hématologie clinique, Hôpital L'Archet, CHU Nice, Nice, France.
Dilhuydy MS; Hématologie clinique, CHU Bordeaux, Bordeaux, France.
Véronèse L; Laboratoire de cytogénétique, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Pereira B; Département de Biostatistiques, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Amorim S; Hématologie clinique, APHP Saint-Louis, Paris, France.
Cymbalista F; Hématologie biologique, APHP Avicenne, Bobigny, France.
Herbaux C; Service des maladies du sang, CHRU de Lille, Lille, France.
de Guibert S; Service d'hématologie clinique, CHU Rennes, Rennes, France.
Roos-Weil D; Sorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, APHP, Paris, France.
Hivert B; Hématologie clinique, Hôpital Saint-Vincent de Paul, Lille, France.
Aurran T; Hématologie clinique, Institut Paoli-Calmettes, Marseille, France.
Dupuis J; Hématologie clinique, APHP Henri Mondor, Créteil, France.
Blouet A; Onco-hématologie, CH de Cholet, Cholet, France.
Tchernonog E; Hématologie clinique, CHU Montpellier, Montpellier, France.
Laribi K; Hématologie clinique, CH Le Mans, Le Mans, France.
Dmytruck N; Hématologie clinique et thérapie cellulaire, CHU Limoges, Limoges, France.
Morel P; Hématologie Clinique et thérapie cellulaire, CHU Amiens, Amiens, France.
Michallet AS; Service d'hématologie, Centre Léon Bérard, Lyon, France.
Dartigeas C; Service hématologie et thérapie cellulaire, CHU Tours, Tours, France.
Tournilhac O; Service d'Hématologie clinique adultes et thérapie cellulaire, Hôpital Estaing, CHU Clermont-Ferrand, 1 place Lucie Aubrac, 63000, Clermont-Ferrand, France.; Université Clermont Auvergne, Clermont-Ferrand, France.
Nguyen-Khac F; Sorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, APHP, Paris, France.
Delmer A; Hématologie clinique, CHU Reims, Reims, France.
Feugier P; Hématologie, CHU de Nancy, Nancy, France.
Ysebaert L; Hématologie clinique, IUCT Oncopole, Toulouse, France.
Guièze R; Service d'Hématologie clinique adultes et thérapie cellulaire, Hôpital Estaing, CHU Clermont-Ferrand, 1 place Lucie Aubrac, 63000, Clermont-Ferrand, France. .; Université Clermont Auvergne, Clermont-Ferrand, France. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 987-993. Date of Electronic Publication: 2021 Jan 25.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Sulfonamides/*therapeutic use
Abnormal Karyotype ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Compassionate Use Trials ; Drug Evaluation ; Female ; France ; Genes, p53 ; Hematopoietic Stem Cell Transplantation ; Humans ; Infections/etiology ; Kaplan-Meier Estimate ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Lymphoma, Large B-Cell, Diffuse/etiology ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/therapy ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies ; Sulfonamides/adverse effects ; Treatment Outcome ; Tumor Lysis Syndrome/etiology
Czasopismo naukowe
Tytuł :
PET/MRI and genetic intrapatient heterogeneity in head and neck cancers.
Autorzy :
Clasen K; Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany. .
Leibfarth S; Section for Biomedical Physics, Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Hilke FJ; Institute of Medical Genetics and Applied Genomics, Medical Faculty and University Hospital, Eberhard Karls University, Calwerstraße 7, 72076, Tübingen, Germany.
Admard J; Institute of Medical Genetics and Applied Genomics, Medical Faculty and University Hospital, Eberhard Karls University, Calwerstraße 7, 72076, Tübingen, Germany.
Winter RM; Section for Biomedical Physics, Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Welz S; Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.; German Cancer Research Center (DKFZ) partner site Tübingen, German Cancer Consortium (DKTK), Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Gatidis S; German Cancer Research Center (DKFZ) partner site Tübingen, German Cancer Consortium (DKTK), Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.; Department of Diagnostic and Interventional Radiology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Nann D; Institute of Pathology and Neuropathology, Medical Faculty and University Hospital, Eberhard Karls University, Liebermeisterstraße 8, 72076, Tübingen, Germany.
Ossowski S; Institute of Medical Genetics and Applied Genomics, Medical Faculty and University Hospital, Eberhard Karls University, Calwerstraße 7, 72076, Tübingen, Germany.; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, C/Dr. Aiguader 88, 08003, Barcelona, Spain.; NGS Competence Center Tübingen (NCCT), Eberhard Karls University, Calwerstraße 7, 72076, Tübingen, Germany.
Breuer T; Department of Otolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital, Eberhard Karls University, Elfriede-Aulhorn-Straße 5, 72076, Tübingen, Germany.
la Fougère C; German Cancer Research Center (DKFZ) partner site Tübingen, German Cancer Consortium (DKTK), Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.; Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, Medical Faculty and University Hospital, Eberhard Karls University, Otfried-Müller-Straße 14, 72076, Tübingen, Germany.
Nikolaou K; German Cancer Research Center (DKFZ) partner site Tübingen, German Cancer Consortium (DKTK), Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.; Department of Diagnostic and Interventional Radiology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Riess O; Institute of Medical Genetics and Applied Genomics, Medical Faculty and University Hospital, Eberhard Karls University, Calwerstraße 7, 72076, Tübingen, Germany.; NGS Competence Center Tübingen (NCCT), Eberhard Karls University, Calwerstraße 7, 72076, Tübingen, Germany.
Zips D; Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.; German Cancer Research Center (DKFZ) partner site Tübingen, German Cancer Consortium (DKTK), Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Schroeder C; Institute of Medical Genetics and Applied Genomics, Medical Faculty and University Hospital, Eberhard Karls University, Calwerstraße 7, 72076, Tübingen, Germany.
Thorwarth D; Section for Biomedical Physics, Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.; German Cancer Research Center (DKFZ) partner site Tübingen, German Cancer Consortium (DKTK), Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Pokaż więcej
Źródło :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2020 Jun; Vol. 196 (6), pp. 542-551. Date of Electronic Publication: 2020 Mar 24.
Typ publikacji :
Journal Article
MeSH Terms :
Genes, Neoplasm*
Genes, p53*
Magnetic Resonance Imaging*
Multimodal Imaging*
Positron-Emission Tomography*
Carcinoma, Squamous Cell/*diagnostic imaging
Oropharyngeal Neoplasms/*diagnostic imaging
Aged ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/secondary ; Carcinoma, Squamous Cell/ultrastructure ; Fluorine Radioisotopes ; Fluorodeoxyglucose F18 ; Genetic Heterogeneity ; Humans ; Male ; Middle Aged ; Mutation ; Neoplasms, Multiple Primary/diagnostic imaging ; Neoplasms, Multiple Primary/genetics ; Neoplasms, Multiple Primary/ultrastructure ; Oropharyngeal Neoplasms/genetics ; Oropharyngeal Neoplasms/ultrastructure ; Pilot Projects ; Prospective Studies ; Radiopharmaceuticals ; Receptor, Notch1/genetics
Czasopismo naukowe
Tytuł :
Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
Autorzy :
Petrackova A; Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Sedlarikova L; Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Libigerova T; Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Hamplova A; Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Krhovska P; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Balcarkova J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Pika T; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Papajik T; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Kriegova E; Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (4), pp. e122-e125. Date of Electronic Publication: 2020 Mar 04.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, p53*
Mutation*
Bone Marrow/*pathology
Multiple Myeloma/*genetics
Tumor Suppressor Protein p53/*genetics
Adult ; Aged ; Aged, 80 and over ; Female ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Male ; Middle Aged ; Multiple Myeloma/pathology
Raport
Tytuł :
A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence.
Autorzy :
Surakhy M; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Wallace M; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Bond E; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Grochola LF; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.; Department of Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland.
Perez H; Faculty of Technology, Design and Environment, Oxford Brookes University, Oxford, UK.
Di Giovannantonio M; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Zhang P; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Malkin D; Division of Hematology/Oncology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Canada.
Carter H; Division of Medical Genetics, Department of Medicine, University of California, San Diego, USA.
Parise IZS; Instituto de Pesquisa Pelé Pequeno Príncipe, Faculdades Pequeno Príncipe, Curitiba, Brazil.
Zambetti G; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Komechen H; Instituto de Pesquisa Pelé Pequeno Príncipe, Faculdades Pequeno Príncipe, Curitiba, Brazil.
Paraizo MM; Instituto de Pesquisa Pelé Pequeno Príncipe, Faculdades Pequeno Príncipe, Curitiba, Brazil.
Pagadala MS; Division of Medical Genetics, Department of Medicine, University of California, San Diego, USA.
Pinto EM; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Lalli E; Institut de Pharmacologie Moléculaire et Cellulaire CNRS, Université Côte D'Azur, Inserm, Valbonne, France.
Figueiredo BC; Instituto de Pesquisa Pelé Pequeno Príncipe, Faculdades Pequeno Príncipe, Curitiba, Brazil. .; Departamento de Saúde Coletiva, Universidade Federal do Paraná, Curitiba, PR, Brazil. .; Centro de Genética Molecular e Pesquisa do Câncer em Crianças (CEGEMPAC), Curitiba, PR, Brazil. .
Bond GL; Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. .
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2020 Apr; Vol. 122 (8), pp. 1231-1241. Date of Electronic Publication: 2020 Mar 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, p53*
Polymorphism, Single Nucleotide*
Adrenal Cortex Neoplasms/*genetics
Adrenocortical Carcinoma/*genetics
Tretinoin/*physiology
Adolescent ; Adrenal Cortex Neoplasms/epidemiology ; Adrenocortical Carcinoma/epidemiology ; Age Factors ; Age of Onset ; Alcohol Dehydrogenase/genetics ; Child ; Child, Preschool ; Female ; Genome-Wide Association Study ; Humans ; Incidence ; Infant ; Male
Czasopismo naukowe
Tytuł :
Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.
Autorzy :
Tamura RE; Viral Vector Laboratory, Center for Translational Investigation in Oncology/LIM24, Cancer Institute of São Paulo, School of Medicine, University of São Paulo, SP, Brazil.; Department of Biological Sciences, Federal University of São Paulo, Diadema, SP, Brazil.
Lana MG; Viral Vector Laboratory, Center for Translational Investigation in Oncology/LIM24, Cancer Institute of São Paulo, School of Medicine, University of São Paulo, SP, Brazil.
Costanzi-Strauss E; Gene Therapy Laboratory, Department of Cell and Developmental Biology, Biomedical Sciences Institute, University of São Paulo, SP, Brazil.
Strauss BE; Viral Vector Laboratory, Center for Translational Investigation in Oncology/LIM24, Cancer Institute of São Paulo, School of Medicine, University of São Paulo, SP, Brazil. .
Pokaż więcej
Źródło :
Gene therapy [Gene Ther] 2020 Feb; Vol. 27 (1-2), pp. 15-26. Date of Electronic Publication: 2019 Mar 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, p53/*genetics
Prostatic Neoplasms/*therapy
Taxoids/*pharmacology
Animals ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Apoptosis/drug effects ; Cell Line, Tumor ; Disease-Free Survival ; Drug Therapy, Combination/methods ; Gene Expression Regulation, Neoplastic/genetics ; Genes, p53/immunology ; Genetic Therapy/methods ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Prostate/pathology ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Taxoids/metabolism ; Tumor Suppressor Protein p53/metabolism ; Xenograft Model Antitumor Assays/methods
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies